Standards & Regulation

Prescription drug abuse has already reached epidemic proportions in the US – and other countries look set to follow the dangerous trend.

How did the NIH get it so wrong – and how can it move on?

Pharmaceutical and regulatory professionals around the world must speak the same language.

Is pharma keeping up with the latest innovations? US legislators say no, and are looking to a new act to accelerate approvals.

In this paper, the authors describe the use of laser diffraction to analyse dry powder behaviour.

The rise of biosimilars is great news for overburdened healthcare systems, but it’s a very different proposition to a simple generic.

In this white paper we examine the deformulation workflow, demonstrating the value of the technique of Morphologically Directed Raman Spectroscopy (MDRS) within this context.

But can pharma manufacturers do more to help prevent medication errors?

FDA scolds company for revealing interim trial results

Just how prevalent is pharmacogenomic information on European drug labels?